Inotuzumab ozogamicin

Therapeutic indications

Inotuzumab ozogamicin is indicated for:

CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL)

Population group: only adults (18 years old or older)

Inotuzumab ozogamicin is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Inotuzumab ozogamicin is contraindicated in the following cases:

Venoocclusive liver disease/sinusoidal obstruction syndrome (VOD/SOS), cirrhosis, nodular regenerative hyperplasia, hepatitis

at least one of
Veno-occlusive disease of the liver
Cirrhosis of liver
Nodular regenerative hyperplasia of liver
Inflammatory disorder of liver

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2020: BESPONSA Powder for concentrate for solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈